Cargando…
MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial
For rare cancers, challenges in establishing standard therapies are greater than those for major cancers, and effective methods are needed. MASTER KEY Project is a multicenter study based in Japan, with two main parts: prospective registry study and multiple clinical trials. Advanced rare cancers, c...
Autores principales: | Okuma, Hitomi S., Yonemori, Kan, Narita, Shoko N., Sukigara, Tamie, Hirakawa, Akihiro, Shimizu, Toshio, Shibata, Taro, Kawai, Akira, Yamamoto, Noboru, Nakamura, Kenichi, Nishida, Toshiro, Fujiwara, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484913/ https://www.ncbi.nlm.nih.gov/pubmed/32112563 http://dx.doi.org/10.1002/cpt.1817 |
Ejemplares similares
-
Drug induced interstitial lung disease in oncology phase I trials
por: Yonemori, Kan, et al.
Publicado: (2016) -
Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019) -
First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data
por: Noda-Narita, Shoko, et al.
Publicado: (2021) -
Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project
por: Okuma, Hitomi S., et al.
Publicado: (2019) -
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials
por: Hirakawa, Akihiro, et al.
Publicado: (2017)